Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials
Copyright policy )Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials
In 2004, circulating tumor cells (CTC) enumeration by the CellSearch® technique at baseline and during treatment was reported to be associated with prognosis in metastatic breast cancer patients. In 2008, the first evidence of the impact of CTC detection by this technique on survival of cM0(i+) patients were reported. These findings were confirmed by other non-interventional studies, whereas CTC were also investigated as a surrogate for tumor biology, mainly for HER2 expression/amplification. The aim of this report is to present the current prospective large interventional studies that have been specifically designed to demonstrate that CTC enumeration/characterization may improve the management of breast cancer patients: STIC CTC METABREAST (France) and Endocrine Therapy Index (USA) assess the CTC-guided hormone therapy vs chemotherapy decision in M1 patients; SWOG0500 (USA) and CirCe01 (France) assess the CTC count changes during treatment in metastatic patients; DETECT III (M1 patients, Germany) and Treat CTC (cM0(i+) patients, European Organization for Research and Treatment of Cancer/Breast International Group) assess the use of anti-HER2 treatments in HER2-negative breast cancer patients selected on the basis of CTC detection/characterization. These trials have different designs in various patient populations but are expected to be the pivotal trials for CTC implementation in the routine management of breast cancer patients.
- Michigan Medicine United States
- Institut National de la Santé et la Recherche Médicale France
- University Hospital of Montpellier France
- University of Paris France
- Heinrich Heine University Düsseldorf Germany
Cancer Research, CirCe XXX1, 610, CellSearch®, CirCe 01, Antineoplastic Agents, Breast Neoplasms, CirCe T-DM1, circulating tumor cells, Neoplastic Cells, Non-Thematic Review, Breast Neoplasms -- diagnosis -- drug therapy -- pathology, ETI score, Breast cancer, breast cancer, TREAT CTC, [SDV.CAN] Life Sciences [q-bio]/Cancer, CirCeXXX1, STIC CTC METABREAST, Humans, STIC CTC, CirCe01, Clinical Trials as Topic, phase III trials., cancer du sein, Circulating -- pathology, Circulating tumor cells, Detect III, Neoplastic Cells, Circulating, CTC, United States, Cancérologie, Europe, CirCeT-DM1, Treatment Outcome, cellules tumorales circulantes, Oncology, Antineoplastic Agents -- therapeutic use, Neoplastic Cells, Circulating -- pathology, Female, phase III trials
Cancer Research, CirCe XXX1, 610, CellSearch®, CirCe 01, Antineoplastic Agents, Breast Neoplasms, CirCe T-DM1, circulating tumor cells, Neoplastic Cells, Non-Thematic Review, Breast Neoplasms -- diagnosis -- drug therapy -- pathology, ETI score, Breast cancer, breast cancer, TREAT CTC, [SDV.CAN] Life Sciences [q-bio]/Cancer, CirCeXXX1, STIC CTC METABREAST, Humans, STIC CTC, CirCe01, Clinical Trials as Topic, phase III trials., cancer du sein, Circulating -- pathology, Circulating tumor cells, Detect III, Neoplastic Cells, Circulating, CTC, United States, Cancérologie, Europe, CirCeT-DM1, Treatment Outcome, cellules tumorales circulantes, Oncology, Antineoplastic Agents -- therapeutic use, Neoplastic Cells, Circulating -- pathology, Female, phase III trials
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).522 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 1% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Top 1% impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 0.1%
Citations provided by BIP!Popularity provided by BIP!